BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 16386902)

  • 21. Pharmacophore modelling of 17beta-HSD1 enzyme based on active inhibitors and enzyme structure.
    Karkola S; Alho-Richmond S; Wahala K
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):225-8. PubMed ID: 18822344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1).
    Bey E; Marchais-Oberwinkler S; Werth R; Negri M; Al-Soud YA; Kruchten P; Oster A; Frotscher M; Birk B; Hartmann RW
    J Med Chem; 2008 Nov; 51(21):6725-39. PubMed ID: 18855374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
    Bey E; Marchais-Oberwinkler S; Kruchten P; Frotscher M; Werth R; Oster A; Algül O; Neugebauer A; Hartmann RW
    Bioorg Med Chem; 2008 Jun; 16(12):6423-35. PubMed ID: 18514529
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and preliminary evaluation of a modified estradiol-core bearing a fused γ-lactone as non-estrogenic inhibitor of 17β-hydroxysteroid dehydrogenase type 1.
    Ouellet E; Ayan D; Poirier D
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5510-3. PubMed ID: 21782424
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel and potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.
    Lawrence HR; Vicker N; Allan GM; Smith A; Mahon MF; Tutill HJ; Purohit A; Reed MJ; Potter BV
    J Med Chem; 2005 Apr; 48(8):2759-62. PubMed ID: 15828812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of phthalates on 3β-hydroxysteroid dehydrogenase and 17β-hydroxysteroid dehydrogenase 3 activities in human and rat testes.
    Yuan K; Zhao B; Li XW; Hu GX; Su Y; Chu Y; Akingbemi BT; Lian QQ; Ge RS
    Chem Biol Interact; 2012 Feb; 195(3):180-8. PubMed ID: 22214983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of oxazolidinediones and thiazolidinediones as potent 17β-hydroxysteroid dehydrogenase type 3 inhibitors.
    Harada K; Kubo H; Tanaka A; Nishioka K
    Bioorg Med Chem Lett; 2012 Jan; 22(1):504-7. PubMed ID: 22137341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of chemically diverse, novel inhibitors of 17β-hydroxysteroid dehydrogenase type 3 and 5 by pharmacophore-based virtual screening.
    Schuster D; Kowalik D; Kirchmair J; Laggner C; Markt P; Aebischer-Gumy C; Ströhle F; Möller G; Wolber G; Wilckens T; Langer T; Odermatt A; Adamski J
    J Steroid Biochem Mol Biol; 2011 May; 125(1-2):148-61. PubMed ID: 21300150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibitory effects of fluorine-substituted estrogens on the activity of 17beta-hydroxysteroid dehydrogenases.
    Deluca D; Möller G; Rosinus A; Elger W; Hillisch A; Adamski J
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):218-24. PubMed ID: 16406285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design and synthesis of bisubstrate inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: overview and perspectives.
    Fournier D; Poirier D; Mazumdar M; Lin SX
    Eur J Med Chem; 2008 Nov; 43(11):2298-306. PubMed ID: 18372081
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The derivation of a potential transition state for the reduction reaction catalysed by 17beta-hydroxysteroid dehydrogenase--an approximate representation of its active site for use in drug design and discovery.
    Owen CP; Ahmed S
    Biochem Biophys Res Commun; 2004 May; 318(1):131-4. PubMed ID: 15110763
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and biological evaluation of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core.
    Lilienkampf A; Karkola S; Alho-Richmond S; Koskimies P; Johansson N; Huhtinen K; Vihko K; Wähälä K
    J Med Chem; 2009 Nov; 52(21):6660-71. PubMed ID: 19824648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Curcumin derivatives inhibit testicular 17beta-hydroxysteroid dehydrogenase 3.
    Hu GX; Liang G; Chu Y; Li X; Lian QQ; Lin H; He Y; Huang Y; Hardy DO; Ge RS
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2549-51. PubMed ID: 20346654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, chemical synthesis and biological evaluation of 3-spiromorpholinone/3-spirocarbamate androsterone derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 3.
    Djigoué GB; Kenmogne LC; Roy J; Maltais R; Poirier D
    Bioorg Med Chem; 2015 Sep; 23(17):5433-51. PubMed ID: 26277760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A 3D QSAR model of 17beta-HSD1 inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core applying molecular dynamics simulations and ligand-protein docking.
    Karkola S; Lilienkampf A; Wähälä K
    ChemMedChem; 2008 Mar; 3(3):461-72. PubMed ID: 18224704
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure-activity study in the class of 6-(3'-hydroxyphenyl)naphthalenes leading to an optimization of a pharmacophore model for 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors.
    Marchais-Oberwinkler S; Frotscher M; Ziegler E; Werth R; Kruchten P; Messinger J; Thole H; Hartmann RW
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):205-11. PubMed ID: 18950679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of type 2 17beta-hydroxysteroid dehydrogenase by estradiol derivatives bearing a lactone on the D-ring: structure-activity relationships.
    Bydal P; Auger S; Poirier D
    Steroids; 2004 May; 69(5):325-42. PubMed ID: 15219411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Caenorhabditis elegans LET-767 is able to metabolize androgens and estrogens and likely shares common ancestor with human types 3 and 12 17beta-hydroxysteroid dehydrogenases.
    Desnoyers S; Blanchard PG; St-Laurent JF; Gagnon SN; Baillie DL; Luu-The V
    J Endocrinol; 2007 Nov; 195(2):271-9. PubMed ID: 17951538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 17β-HSD2 inhibitors for the treatment of osteoporosis: Identification of a promising scaffold.
    Wetzel M; Marchais-Oberwinkler S; Hartmann RW
    Bioorg Med Chem; 2011 Jan; 19(2):807-15. PubMed ID: 21211981
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of fused 16β,17β-oxazinone-estradiol derivatives as a new family of non-estrogenic 17β-hydroxysteroid dehydrogenase type 1 inhibitors.
    Maltais R; Trottier A; Delhomme A; Barbeau X; Lagüe P; Poirier D
    Eur J Med Chem; 2015 Mar; 93():470-80. PubMed ID: 25728028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.